KRIS MAGPANTAY: Open Payments
NPI 1598240269 · LAWRENCEVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,926 in 313 payments from 19 companies in 2025. Trend: 2023 $2,109 · 2024 $3,707 · 2025 $4,926
Food & beverage: $4,734Education: $193
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 71 | $876 |
| Supernus Pharmaceuticals, Inc. | 52 | $612 |
| Alkermes, Inc. | 27 | $575 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 32 | $541 |
| E.R. Squibb & Sons, L.L.C. | 21 | $384 |
| ABBVIE INC. | 20 | $369 |
| Neurocrine BioSciences, Inc. | 29 | $349 |
| Vanda Pharmaceuticals Inc. | 13 | $244 |
| Bausch Health US, LLC | 10 | $215 |
| Otsuka America Pharmaceutical, Inc. | 10 | $197 |
Products named: Qelbree, CAPLYTA, UZEDY, ARISTADA, COBENFY, VRAYLAR, INGREZZA, AUSTEDO XR.
Industry payments across GA — which companies pay providers there.
